The U.S. Food and Drug Administration has extended the review period for Eisai's supplemental Biologics License Application for Leqembi Iqlik ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE